col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


299 Results       Page 1

 [1] 
Elsevier: Multiple Sclerosis and Related Disorders
  original article Date Title Authors   All Authors
1 [GO] 2024―Apr―08 SARS-CoV-2 infection increases long-term multiple sclerosis disease activity and all-cause mortality in an underserved inner-city population Roham Hadidchi, Stephen H. Wang, David Rezko, Sonya Henry, Patricia K. Coyle, Tim Q. Duong
2 [GO] 2024―Mar―08 Breakthrough COVID-19 in people with multiple sclerosis on disease modifying treatments: is it still a severe disease? Paolo Immovilli, Irene Schiavetti, Alessandro Franceschini, Paola De Mitri, Lorenza Gelati, Eugenia Rota, Donata Guidetti
3 [GO] 2024―Jan―25 Risk of MS relapse and deterioration after COVID-19: A systematic review and meta-analysis Homa Seyedmirzaei, Dorsa Salabat, Sara KamaliZonouzi, Antônio L. Teixeira, Nima Rezaei
4 [GO] 2023―Dec―18 COVID-19 Infection, Acute Relapse, and Adverse Effects Following COVID-19 Vaccination in Patients with Multiple Sclerosis and Other Neurological Disorders Mohammad Yazdan Panah, Saeed Vaheb, Yousef Mokary, Elham Moases Ghaffary, Alireza Afshari-Safavi, Aysa Shaygannejad, et al. (+3)
5 [GO] 2023―Dec―18 Incidence and Severity of COVID-19 Infection After Pulse Methylprednisolone in Patients with Multiple Sclerosis Maryam Poursadeghfard, Mahnaz Bayat, Razieh Shafaei
6 [GO] 2023―Dec―18 Acute Relapses of Neuromyelitis Optica Spectrum Disorder After COVID-19 Vaccination Shot, a Case Series from Iran Roshanak Mehdipour
7 [GO] 2023―Nov―10 The Impact of COVID-19 on a Southern Chinese Cohort with Neuromyelitis Optica Spectrum Disorders Jian Zhong, Yu Wu, Shaodan Zhou, Chao Liu, Yishuang Wen, Manli Liang, et al. (+8)
8 [GO] 2023―Nov―05 The Effect of COVID-19 on Multiple Sclerosis Relapse: A Systematic Review and Meta-analysis Sepehr Aghajanian, Arman Shafiee, Amirhossein Akhondi, Shahryar Rajai Firouz Abadi, Ida Mohammadi, Muhammad Ehsan, Fatemeh Mohammadifard
9 [GO] 2023―Oct―16 Indirect Impact of the COVID-19 pandemic on the care and outcomes of people with MS: a combined survey and insurance claims study Ethan Meltzer, Odelin Charron, Joe Wozny, Helen Onuorah, Amanda Montague, Alexis Crispino Kline, et al. (+3)
10 [GO] 2023―Sep―25 Patients with multiple sclerosis: COVID-19 related disease activity and hospitalisations based on a nationwide cohort study Mette Louise Andersen, Floor Dijkstra Zegers, Line Riis Jølving, Torben Knudsen, Egon Stenager, Bente Mertz Nørgård
11 [GO] 2023―Sep―06 Post-vaccination SARS-Cov-2 T-cell receptor repertoires and multiple sclerosis and related disorders: correspondence Amnuay Kleebayoon, Viroj Wiwanitkit
12 [GO] 2023―Aug―29 Humoral immune response to COVID-19 mRNA vaccines in patients with relapsing multiple sclerosis treated with ofatumumab Amit Bar-Or, Rany Aburashed, Angel R. Chinea, Barry A. Hendin, Elisabeth Lucassen, Xiangyi Meng, et al. (+3)
13 [GO] 2023―Aug―29 Post-vaccination SARS-Cov-2 T-cell receptor repertoires in patients with multiple sclerosis and related disorders Priyanka Algu, Natasha Hameed, Tracy DeAngelis, Joel Stern, Asaff Harel
14 [GO] 2023―Aug―24 Anti-SARS-CoV-2 monoclonal antibodies for the treatment of mild-to-moderate COVID-19 in multiple sclerosis: A retrospective cohort study Harry Jin, Caroline Geiger, Nikki Jessop, Rosetta Pedotti, Catarina Raposo, Louise Whitley, et al. (+2)
15 [GO] 2023―Aug―19 Multiple sclerosis is associated with worse COVID-19 outcomes compared to the general population: A population-based study Mahdi Barzegar, Setayesh Sindarreh, Amirreza Manteghinejad, Omid Mirmosayyeb, Shahrbanoo Mazaheri, Maryam Rahimi, et al. (+3)
16 [GO] 2023―Aug―01 The effect of COVID-19 lockdowns on exercise and the role of online exercise in Australians with multiple sclerosis MG Panisset, MP Galea
17 [GO] 2023―Jul―14 Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey Manuela Altieri, Rocco Capuano, Alvino Bisecco, Alessandro d'Ambrosio, Mario Risi, Paola Cavalla, et al. (+20)
18 [GO] 2023―Jul―13 Real-world use of ofatumumab to treat multiple sclerosis 9 months post-FDA approval during COVID-19 pandemic Patricia K. Coyle, Magdaliz Gorritz, Rolin L. Wade, Zifan Zhou, Subhan Khalid, Eric M. Maiese, et al. (+2)
19 [GO] 2023―Jul―02 Incidence of Multiple Sclerosis Relapses and Pseudo-Relapses following COVID-19 Vaccination Amir Labani, Scott Chou, Kasra Kaviani, Brenda Ropero, Katharine Russman, Daniel Becker
20 [GO] 2023―Jun―10 The Psychological Impact of the COVID-19 Pandemic on People with Multiple Sclerosis Vitalie Vacaras, Cristina Nistor, Andra Maria Schiopu, Cristiana Vacaras, Gheorghe-Eduard Marin, Dafin F Muresanu
21 [GO] 2023―May―10 mRNA versus inactivated virus COVID-19 vaccines in multiple sclerosis: humoral responses and protectivity-Does it matter? Melih Tütüncü, Serkan Demir, Gökhan Arslan, Öykü Dinç, Sedat Şen, Tuncay Gündüz, et al. (+27)
22 [GO] 2023―Apr―10 SARS-CoV-2 pandemic as a model to assess the relationship between intercurrent viral infections and disease activity in Multiple Sclerosis: A propensity score matched case-control study Marco Vercellino, Chiara Bosa, Anastasia Alteno, Francesco Muccio, Stella Marasciulo, Paola Garelli, Paola Cavalla
23 [GO] 2023―Apr―07 Experiences of persons with multiple sclerosis with the Covid-19 vaccination: A cross-sectional study of the Swiss Multiple Sclerosis Registry Mina Stanikić, Eric Twomey, Milo A. Puhan, Christian P. Kamm, Anke Salmen, Vladeta Ajdacic-Gross, et al. (+3)
24 [GO] 2023―Mar―31 Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of COVID-19 in Multiple Sclerosis: A MENACTRIMS Registry Based Study Maya Zeineddine, Farid Boumediene, Amal Al-Hajje, Pascale Salameh, Joelle Massouh, Georges Saab, et al. (+11)
25 [GO] 2023―Mar―31 Real-World Experience on the Use of COVID-19 Vaccination in Multiple Sclerosis Patients Treated with Cladribine Tablets Participating in the ADVEVA® Patient Support Program within the Gulf and Latin American Regions María Isabel Zuluaga Rodas, Laura Negrotto, Mariana Deramo, Jihad Inshasi, Amir Boshra, Joseph Youssef, et al. (+3)
26 [GO] 2023―Mar―31 Use of Social Media Tools during COVID-19 Pandemic Among MS Fellowships and Patients Mahdieh Mokhberdezfuli, Mohammad Ali Sahrian, Abdorreza Naser Moghadasi
27 [GO] 2023―Mar―31 Is Body Mass Index (BMI) Associated with Risk and Outcomes of COVID-19 in Iranian Multiple Sclerosis Patients? Nasim Rezaeimanesh, Naghmeh Abbasi, Mohammad Ali Sahraian, Amirreza Azimi, Abdorreza Naser Moghadasi
28 [GO] 2023―Mar―31 CNS Complications Following COVID-19 Vaccines: an Egyptian Case Series. Sara Salama, Salma S. Almashad, Farouk Talaat, Ismail Ramadan, Sameh M. Siad, Aya Abdelgaleel
29 [GO] 2023―Mar―31 Role of Type 1 Interferons therapy on Adverse Clinical Outcomes on COVID-19 in Hospitalized Multiple Sclerosis Patients Zhila Maghbooli, Mohammad Ali. Sahraian, Mohammad Reza Fattahi, Tarlan Varzandi, Sara Hamtaeigashi, Sara Mohammad-Nabi, Yasaman Aghababaei
30 [GO] 2023―Mar―31 Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-Cov-2 in Patients with Multiple Sclerosis on B-Cell Depleters William L. Conte, Lilian Golzarri-Arroyo
31 [GO] 2023―Mar―12 In-depth characterization of long-term humoral and cellular immune responses to COVID-19 m-RNA vaccination in multiple sclerosis patients treated with teriflunomide or alemtuzumab Anat Achiron, Mathilda Mandel, Sapir Dreyer-Alster, David Magalashvili, Shay Menascu, Yehuda Warszawer, et al. (+6)
32 [GO] 2023―Feb―25 Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: a monocentric experience Andrea Bertozzi, Alice Mariottini, Leonardo Marchi, Maria Di Cristinzi, Riccardo Nistri, Valentina Damato, et al. (+4)
33 [GO] 2023―Feb―15 A retrospective evaluation of seroconversion after COVID-19 during the early Omicron wave in fully vaccinated multiple sclerosis patients receiving anti-CD20 therapies Sharon Stoll, Shree Desai, Elle Levit
34 [GO] 2023―Feb―14 Corrigendum to ’To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection’[Multiple sclerosis and related disorders vol. 65 (2022) 104014] Dominika Stastna, Ingrid Menkyova, Jiri Drahota, Tereza Hrnciarova, Eva Kubala Havrdova, Marta Vachova, et al. (+17)
35 [GO] 2023―Feb―13 Impact of COVID-19 on Prescribing Patterns and Treatment Selection of Disease Modifying Therapies in Multiple Sclerosis Reemal Zaheer, Roma Amin, LaTasha Riddick, Shuvro Roy, Sujin Wolff, Amy Nathanson, Scott Newsome
36 [GO] 2023―Feb―03 Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study Mahdi Barzegar, Amirreza Manteghinejad, Alireza Afshari-Safavi, Omid Mirmosayyeb, Maryam Nasirian, Sara Bagherieh, et al. (+5)
37 [GO] 2023―Jan―25 Changes in physiotherapy services and use of technology for people with multiple sclerosis during the COVID-19 pandemic Johanna Jonsdottir, Carme Santoyo-Medina, Turhan Kahraman, Alon Kalron, Kamila Rasova, Lousin Moumdjian, et al. (+9)
38 [GO] 2023―Jan―11 Electronic health record data for assessing risk of hospitalization for COVID-19: methodological considerations applied to multiple sclerosis Paul Dillon, Athanasios Siadimas, Spyros Roumpanis, Otto Fajardo, Kocho Fitovski, Nikki Jessop, et al. (+2)
39 [GO] 2023―Jan―05 The effect of telenursing education of self-care on health-promoting behaviors in patients with multiple sclerosis during the COVID-19 pandemic: A clinical trial study Ali Dehghani, Yasaman Pourfarid, Mohsen Hojat
40 [GO] 2022―Dec―30 Safety of inactivated COVID-19 vaccines in autoimmune encephalitis: a real-world cross-sectional survey Xu Liu, Kun dian Guo, Lu Lu, Rong Luo, Jie Liu, Dong Zhou, Zhen Hong
41 [GO] 2022―Dec―30 CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis Irene Schiavetti, Lucrezia Barcellini, Caterina Lapucci, Francesco Tazza, Maria Cellerino, Elisabetta Capello, et al. (+5)
42 [GO] 2022―Dec―28 Longitudinal adaptive immune responses following sequential SARS-CoV-2 vaccinations in MS patients on anti-CD20 therapies and sphingosine-1-phosphate receptor modulators Joseph J. Sabatino, Kristen Mittl, William Rowles, Colin R. Zamecnik, Rita P. Loudermilk, Chloe Gerungan, et al. (+11)
43 [GO] 2022―Dec―28 Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy Ilana Katz Sand, Sacha Gnjatic, Florian Krammer, Kevin Tuballes, Juan Manuel Carreño, Sammita Satyanarayan, et al. (+15)
44 [GO] 2022―Dec―25 QUALITY OF LIFE AND MENTAL HEALTH IN MULTIPLE SLCEROSIS PATIENTS DURING THE COVID-19 PANDEMIC. Yaneth Rodríguez-Agudelo, Jaqueline Nava-Adán, Francisco Paz-Rodríguez, Arturo Abundes-Corona, José Flores-Rivera, Teresa Corona
45 [GO] 2022―Nov―22 The impact of sphinogosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination David Baker, Eugenia Forte, Gareth Pryce, Angray S. Kang, Louisa K. James, Gavin Giovannoni, Klaus Schmierer
46 [GO] 2022―Oct―26 JCV Seroconversion rate during the SARS COVID-19 Pandemic I. Vigiser, Y. Piura, H. Kolb, T. Shiner, I. Komarov, A. Karni, K. Regev
47 [GO] 2022―Oct―23 Humoral efficacy of the third SARS-CoV-2 vaccine dose in Multiple Sclerosis subjects undergoing different disease-modifying therapies Giorgia Teresa Maniscalco, Antonietta Liotti, Anne Lise Ferrara, Elio Prestipino, Simona Salvatore, Maria Elena Di Battista, et al. (+9)
48 [GO] 2022―Oct―20 The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: a case-control study Marta Ponzano, Irene Schiavetti, Roberto Bergamaschi, Enrico Pisoni, Andrea Bellavia, Giulia Mallucci, et al. (+33)
49 [GO] 2022―Oct―09 Impact of resilience, social support, and personality traits in patients with neuroinflammatory diseases during the COVID-19 pandemic Dejan Jakimovski, Katelyn S Kavak, Erin E. Longbrake, Elle Levit, Christopher M Perrone, Amit Bar-Or, et al. (+7)
50 [GO] 2022―Oct―08 Vaccination of multiple sclerosis patients during the COVID-19 era: Novel insights into vaccine safety and immunogenicity Enoch Kim, Alyssa Haag, Jackie Nguyen, Marc M. Kesselman, Michelle Demory Beckler
51 [GO] 2022―Sep―26 Longitudinal COVID-19 immune trajectories in patients with neurological autoimmunity on anti-CD20 therapy Sam A. Bazzi, Cole Maguire, Nisha Holay, Janelle Geltman, Kerin Hurley, Chris DiPasquale, et al. (+5)
52 [GO] 2022―Sep―21 Exploring the impact of the COVID-19 pandemic on social isolation and mental health in people with MS Shu Ling, Brandon Moss, Zhini Wang, Amy B. Sullivan
53 [GO] 2022―Sep―15 Impact of Covid-19 emergency on rehabilitation services for Multiple Sclerosis: an international RIMS survey Giampaolo Brichetto, Andrea Tacchino, Letizia Leocani, Daphne Kos
54 [GO] 2022―Sep―14 Relapses after SARS-CoV-2 Vaccination in Patients with Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis. Lingyao Kong, Xiaofei Wang, Hongxi Chen, Ziyan Shi, Yanlin Lang, Ying Zhang, Hongyu Zhou
55 [GO] 2022―Sep―11 Clinical onset of CNS demyelinating disease after COVID-19 vaccination: denovo disease? J.A. Gernert, H. Zimmermann, E. Oswald, T. Christmann, T. Kümpfel, J. Havla
56 [GO] 2022―Sep―10 Vaccination of Multiple Sclerosis Patients During the COVID-19 Era: Novel Insights into Vaccine Safety and Immunogenicity Enoch Kim, Alyssa Haag, Jackie Nguyen, Marc M. Kesselman, Michelle Demory Beckler
57 [GO] 2022―Sep―05 COVID-19 severity among patients with multiple sclerosis treated with cladribine: a systematic review and meta-analysis Angela Albanese, Maria Pia Sormani, Giovanni Gattorno, Irene Schiavetti
58 [GO] 2022―Aug―29 Clinical outcomes of COVID-19 in patients with multiple sclerosis treated with ocrelizumab in the pre- and post-SARS-CoV-2 vaccination periods: insights from Israel Janick Weberpals, Spyros Roumpanis, Yael Barer, Sharon Ehrlich, Nikki Jessop, Rosetta Pedotti, et al. (+4)
59 [GO] 2022―Aug―21 Onset of various CNS inflammatory demyelination diseases following COVID-19 vaccinations Ki Hoon Kim, Su-Hyun Kim, Na Young Park, Jae-Won Hyun, Ho Jin Kim
60 [GO] 2022―Aug―17 Three doses of COVID-19 vaccines in multiple sclerosis patients treated with disease-modifying therapies Cavid Baba, Sinem Ozcelik, Ergi Kaya, Ulvi Samedzada, Asiye Tuba Ozdogar, Sumeyye Cevik, et al. (+2)
61 [GO] 2022―Aug―17 Multiple sclerosis and COVID-19: Assessing risk perception, patient behaviours and access to disease-modifying therapies R Beesley, M Cauchi, L Davies, M Upcott, E Norton, S Loveless, et al. (+8)
62 [GO] 2022―Aug―15 Quantitative and qualitative features of acute phase-adverse events following SARS-CoV-2 vaccination in a large sample of people with multiple sclerosis E. Tavazzi, G. Della Porta, F.S. Robustelli della Cuna, L. Gervasio, E. Guerra, M.A. Tejada Condemayta, et al. (+3)
63 [GO] 2022―Aug―12 Incidence of COVID-19 after vaccination in people with multiple sclerosis in Argentina: data from the nationwide registry RelevarEM Juan I. Rojas, Geraldine G. Luetic, Carlos Vrech, Agustín Pappolla, Liliana Patrucco, Edgardo Cristiano, et al. (+48)
64 [GO] 2022―Aug―11 Fatal Neuromyelitis Optica after COVID-19 vaccination Vinícius de Oliveira Boldrini, Clarissa Lin Yasuda
65 [GO] 2022―Jul―28 Humoral response to COVID-19 vaccination in MS Patients on Disease Modifying Therapy: Immune Profiles and Clinical Outcomes Kathryn B. Holroyd, Brian C. Healy, Sarah Conway, Maria Houtchens, Rohit Bakshi, Shamik Bhattacharyya, et al. (+13)
66 [GO] 2022―Jul―22 Association between disease-modifying therapies and adverse clinical outcomes in multiple sclerosis patients with COVID-19 infection Zhila Maghbooli, Hesham Hosseinpour, Mohammad Reza Fattahi, Tarlan Varzandi, Sara Hamtaeigashi, Sara Mohammad-nabi, et al. (+2)
67 [GO] 2022―Jul―06 Clinical characteristics, radiological features and prognostic factors of transverse myelitis following COVID-19 vaccination: A systematic review Vahid Reza Ostovan, Mohammad Ali Sahraian, Neda Karazhian, Mahtab Rostamihosseinkhani, Marzieh Salimi, Hoda Marbooti
68 [GO] 2022―Jul―05 COVID-19 in the pregnant or postpartum MS patient: Symptoms and Outcomes Amber Salter, Anne H. Cross, Gary R. Cutter, Robert J. Fox, David K.B. Li, Bruce Bebo, et al. (+4)
69 [GO] 2022―Jul―05 COVID-19 infection and vaccination against COVID- 19: Impact on managing demyelinating CNS disorders in Southern India- Experience from a demyelinating disease registry. Pandit L, S Akshatha, C Malli, A. D'Cunha
70 [GO] 2022―Jul―05 Fulminant neuromyelitis optica spectrum disorder (NMOSD) following COVID-19 vaccination: A need for reconsideration? Ali Motahharynia, Saba Naghavi, Vahid Shaygannejad, Iman Adibi
71 [GO] 2022―Jul―03 Did it hurt? COVID-19 vaccination experience in people with multiple sclerosis Allen-Philbey K, Stennett A, Begum T, Johnson AC, MacDougall A, Green S, et al. (+9)
72 [GO] 2022―Jul―02 To be or not to be vaccinated: The risk of MS or NMOSD relapse after COVID-19 vaccination and infection Dominika Stastna, Ingrid Menkyova, Jiri Drahota, Tereza Hrnciarova, Eva Kubala Havrdova, Marta Vachova, et al. (+17)
73 [GO] 2022―Jul―02 Humoral immune response to SARS-CoV-2 third vaccination in patients with multiple sclerosis and healthy controls: a prospective multicenter study Nik Krajnc, Harald Hegen, Gerhard Traxler, Fritz Leutmezer, Franziska Di Pauli, Barbara Kornek, et al. (+13)
74 [GO] 2022―Jun―26 COVID-19 infection after two doses of SARS-CoV-2 mRNA vaccine in Multiple Sclerosis, AQP4-antibody NMOSD and MOGAD Tianrong Yeo, Amy May Lin Quek, Kok Pin Yong, Janis Siew Noi Tye, Pavanni Ratnagopal, Derek Tuck Loong Soon, Kevin Tan
75 [GO] 2022―Jun―21 The disease course of multiple sclerosis before and during COVID-19 pandemic: A retrospective five-year study Fawzi Babtain, Abdulaziz Bajafar, Ohoud Nazmi, Manal Badawi, Ahmed Basndwah, Areej Bushnag, et al. (+2)
76 [GO] 2022―Jun―14 Social support predicts sleep quality in people with multiple sclerosis during the COVID-19 pandemic Taylor P. Harris, Lauren M. Zaeske, Rebecca Ludwig, Sara Baker, Sharon Lynch, Amanda Thuringer, et al. (+2)
77 [GO] 2022―Jun―11 Outcomes of multiple sclerosis patients admitted with COVID-19 in a large veteran cohort Tom A. Fuchs, Bethany A. Wattengel, Michael T. Carter, Ali A. El-Solh, Alan J. Lesse, Kari A. Mergenhagen
78 [GO] 2022―Jun―10 Watch out for neuromyelitis optica spectrum disorder onset or clinical relapse after COVID-19 vaccination: what neurologists need to know? Sepideh Paybast, Ali Emami, Fatemeh Baghalha, Abdorreza Naser Moghadasi
79 [GO] 2022―Jun―06 COVID-19 severity is associated with worsened neurological outcomes in Multiple Sclerosis and Related Disorders Sarah E. Conway, Brian C. Healy, Jonathan Zurawski, Christopher Severson, Tamara Kaplan, Lynn Stazzone, et al. (+3)
80 [GO] 2022―Jun―06 Temelimab for MS and SARS-CoV-2: Could it be a double-edged blessing? Dimitra S. Mouliou, Efthimios Dardiotis
81 [GO] 2022―Jun―04 Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis. Emma C Tallantyre, Martin J Scurr, Nicola Vickaryous, Aidan Richards, Valerie Anderson, David Baker, et al. (+18)
82 [GO] 2022―May―27 Impact of telehealth on health care in a multiple sclerosis outpatient clinic during the COVID-19 pandemic Vivien Li, Izanne Roos, Mastura Monif, Charles Malpas, Stefanie Roberts, Mark Marriott, et al. (+6)
83 [GO] 2022―May―25 A multiparametric score for assessing the individual risk of severe Covid-19 among patients with Multiple Sclerosis. Marta Ponzano, Irene Schiavetti, Francesca Bovis, Doriana Landi, Luca Carmisciano, Nicola De Rossi, et al. (+28)
84 [GO] 2022―May―23 Has the pandemic changed treatment strategy in multiple sclerosis? Gabriel Bsteh, Katharina Riedl, Nik Krajnc, Barbara Kornek, Fritz Leutmezer, Stefan Macher, et al. (+3)
85 [GO] 2022―May―21 Tixagevimab and Cilgavimab (Evusheld) boosts antibody levels to SARS-CoV-2 in patients with multiple sclerosis on b-cell depleters William L. Conte, Lilian Golzarri-Arroyo
86 [GO] 2022―May―19 Telemedicine and Multiple Sclerosis Management in the Era of COVID-19, Al-Azhar Experience Ahmed Essmat
87 [GO] 2022―May―19 Incidence, Severity, Outcomes, and Risk Factors of COVID-19 in Multiple Sclerosis: An Observational Study in the Middle East Raed Alroughani, Jihad Said Inshasi, Jasem Al-Hashel, Jaber Alkhaboury, Abdullah Alsalti, Reem Al Suwaidi, et al. (+2)
88 [GO] 2022―May―19 Epidemiology of COVID-19 in Patients with MS: A Hospital-Based Registry Sharareh Eskandarieh, Nasim Rezaeimanesh, Hora Heydari, Mohammad Hossein Harirchian
89 [GO] 2022―May―19 Association of Multiple Sclerosis and COVID-19 Infection: A Case Report Ismail Ibrahim Ismail, Jasem Al-Hashel, Raed Alroughani, Samar Farouk Ahmed
90 [GO] 2022―May―19 The impact of COVID-19 on people with multiple sclerosis: A comparison of Italian and United States cohorts Carolyn E. Schwartz, Bruce D. Rapkin, Simona Bonavita, Michela Bossa, Maria Chiara Buscarinu, Maria Grazia Grasso, et al. (+3)
91 [GO] 2022―May―19 Medication Adherence Among Patients with Multiple Sclerosis During the COVID-19 Pandemic: Perspective from the Near East Region Murad Al-Naqshbandi, Hoda Joudi, Abed Raki
92 [GO] 2022―May―19 Expert Opinion on COVID-19 Vaccination and the Use of Cladribine Tablets Bassem I Yamout, Peter Rieckmann, Diego Centonze, Gavin Giovannoni, Le H. Hua, Celia Oreja-Guevara, et al. (+4)
93 [GO] 2022―May―19 Real-world experience on the use of COVID-19 vaccination in patients with multiple sclerosis treated with Cladribine tablets in the Gulf region Jihad Inshasi, Amir Boshra, Joseph Youssef
94 [GO] 2022―May―19 COVID-19 Vaccination in People with Multiple Sclerosis. the Kuwait Experience Raed Alroughani, Jasem Al-Hashel, Fathi Abokalawa, Malak Almojel, Samar Farouk Ahmed
95 [GO] 2022―May―19 Association of COVID-19 with Disability Progression and Disease Exacerbation in People with Relapsing-Remitting Multiple Sclerosis: Evidence from a Year-Long Observational Study Nahad Sedaghat, Masoud Etemadifar, Hosein Nouri, Amir Parsa Abhari, Shiva Maleki, Alireza Amin, Mehri Salari
96 [GO] 2022―May―19 Humoral Immune Response to SARS-CoV-2 Vaccination in MS Patients Celia Oreja-Guevara, Judit Díaz-Díaz, Elda Alba Suárez, Irene Gómez-Estévez, Johnny Quezada Sánchez, Cristina Bullón-Sánchez, et al. (+4)
97 [GO] 2022―May―19 The Psychological Effect of COVID19 Pandemic on Neuromyelitis Optica Spectrum Disorder Patients and Their Attitude Change After a Year of the Pandemic in Isfahan, Iran. Roshanak Mehdipour Dastjerdi, Fereshteh Ashtari
98 [GO] 2022―May―17 SARS-CoV-2 infection in patients with neuroimmunological disorders in a tertiary referral centre from the north of Portugal. João Moura, Henrique Nascimento, Inês Ferreira, Raquel Samões, Catarina Teixeira, Dina Lopes, et al. (+4)
99 [GO] 2022―May―10 Longitudinal humoral response in MS patients treated with Cladribine tablets after receiving the second and third doses of SARS-CoV-2 mRNA vaccine Livnat Brill, Ariel Rechtman, Alla Shifrin, Ayal Rozenberg, Svetlana Afanasiev, Omri Zveik, et al. (+3)
100 [GO] 2022―May―06 The influence of COVID-19 pandemic lockdown on the physical activity of people with multiple sclerosis. The role of online training Mariola Matysiak, Małgorzata Siger, Agata Walczak, Agnieszka Ciach, Mateusz Jonakowski, Mariusz Stasiołek
101 [GO] 2022―May―06 Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies Asya I. Wallach, Matthew Schiebel, Mary Ann Picone
102 [GO] 2022―Apr―25 Safety profile of SARS-CoV-2 vaccination in patients with antibody-mediated CNS disorders Alessandro Dinoto, Matteo Gastaldi, Raffaele Iorio, Sofia Marini, Valentina Damato, Antonio Farina, et al. (+8)
103 [GO] 2022―Apr―13 Long term persistence of SARS-CoV-2 humoral response in Multiple Sclerosis subjects Giorgia Teresa Maniscalco, Anne Lise Ferrara, Antonietta Liotti, Valentino Manzo, Maria Elena Di Battista, Simona Salvatore, et al. (+10)
104 [GO] 2022―Apr―11 How important are COVID-19 vaccine responses in patients with MS on disease-modifying therapies? Gavin Giovannoni
105 [GO] 2022―Apr―10 Hypogammaglobulinemia, infections and COVID-19 in people with multiple sclerosis treated with ocrelizumab Mario Habek, Dominik Piskač, Tereza Gabelić, Barbara Barun, Ivan Adamec, Magdalena Krbot Skorić
106 [GO] 2022―Apr―10 The impact of the COVID-19 pandemic on physical therapy practice for people with multiple sclerosis: A multicenter survey study of the RIMS network Turhan Kahraman, Kamila Rasova, Johanna Jonsdottir, Carme Santoyo Medina, Daphne Kos, Susan Coote, et al. (+8)
107 [GO] 2022―Apr―06 Autoimmune encephalitis associated with COVID-19: A systematic review Fardin Nabizadeh, Mohammad Balabandian, Fatemeh Sodeifian, Negin Rezaei, Mohammad Reza Rostami, Abdorreza Naser Moghadasi
108 [GO] 2022―Apr―06 HUMORAL RESPONSE TO SARS-COV-2 INFECTION AND VACCINES AGAINST COVID-19 IN PATIENTS WITH NEUROMYELITIS OPTICA SPECTRUM DISORDERS: IMPACT OF IMMUNOSUPPRESSIVE TREATMENT Vanja Jovicevic, Jovana Ivanovic, Nikola Momcilovic, Marko Andabaka, Olivera Tamas, Nikola Veselinovic, et al. (+5)
109 [GO] 2022―Mar―30 The Humoral Response to SARS-COV-2 Vaccines in MS Patients: A Case Series Exploring the Impact of DMT, Lymphocyte Count, Immunoglobulins, and Vaccine Type Collin Jakubecz, Xiaochun Susan Zhang, Sophia Woodson, Alessandro Serra, Hesham Abboud
110 [GO] 2022―Mar―26 The psychological impact of Covid-19 pandemic on people with Multiple Sclerosis: a meta-analysis Altieri Manuela, Capuano Rocco, Bisecco Alvino, d'Ambrosio Alessandro, Buonanno Daniela, Tedeschi Gioacchino, et al. (+2)
111 [GO] 2022―Mar―13 COVID-19 vaccine associated demyelination & its association with MOG antibody Netravathi M, Dhamija K, Manisha Gupta, Arina Tamborska, Nalini A, VV Holla, et al. (+11)
112 [GO] 2022―Mar―12 Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis Sammita Satyanarayan, Neha Safi, Tali Sorets, Susan Filomena, Yinan Zhang, Sylvia Klineova, et al. (+8)
113 [GO] 2022―Mar―11 Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies Tyler E Smith, Maya Madhavan, Daniel Gratch, Aneek Patel, Valerie Saha, Carrie Sammarco, et al. (+8)
114 [GO] 2022―Mar―07 Persistently reduced humoral and sustained cellular immune response from first to third SARS-CoV-2 mRNA vaccination in anti-CD20-treated multiple sclerosis patients Hamza Mahmood Bajwa, Frederik Novak, Anna Christine Nilsson, Christian Nielsen, Dorte K. Holm, Kamilla Østergaard, et al. (+9)
115 [GO] 2022―Mar―05 COVID-19 vaccine hesitancy in Iranian patients with multiple sclerosis Naghmeh Abbasi, Fereshteh Ghadiri, Abdorreza Naser Moghadasi, Amirreza Azimi, Samira Navardi, Hora Heidari, et al. (+2)
116 [GO] 2022―Mar―04 Six-month humoral response to mRNA SARS-CoV-2 vaccination in Patients with Multiple Sclerosis treated with Ocrelizumab and Fingolimod Rocco Capuano, Alvino Bisecco, Miriana Conte, Giovanna Donnarumma, Manuela Altieri, Elena Grimaldi, et al. (+6)
117 [GO] 2022―Mar―03 Seroconversion after COVID-19 vaccination for multiple sclerosis patients on high efficacy disease modifying medications Elle Levit, Erin E. Longbrake, Sharon S Stoll
118 [GO] 2022―Feb―26 A one year follow of patients with multiple sclerosis during COVID-19 pandemic: A cross-sectional study in Qom province, Iran Sepideh Paybast, Seyed Amir Hejazi, Payam Molavi, Mohammad Amin Habibi, Abdorreza Naser Moghadasi
119 [GO] 2022―Feb―19 Post COVID-19 Infection Neuromyelitis Optica Spectrum Disorder (NMOSD): A Case Report-Based Systematic Review Omid Mirmosayyeb, Elham Moases Ghaffary, Sara Bagherieh, Mahdi Barzegar, Mohammad Sadegh Dehghan, Vahid Shaygannejad
120 [GO] 2022―Feb―19 COVID-19 in neuromyelitis optica spectrum disorder patients in Poland. Aleksandra Podlecka-Piętowska, Krzysztof Barć, Agata Denisiuk, Monika Nojszewska, Beata Zakrzewska-Pniewska
121 [GO] 2022―Feb―19 Real-world data about the side effects of SARS-CoV-2 vaccinations can be obtained only from representative samples undergoing comprehensive investigations Josef Finsterer
122 [GO] 2022―Feb―13 Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis Ethel Ciampi, Reinaldo Uribe-San-Martin, Bernardita Soler, Lorena García, Jorge Guzman, Carolina Pelayo, et al. (+5)
123 [GO] 2022―Feb―08 Humoral and cellular immunity in convalescent and vaccinated COVID-19 people with multiple sclerosis: effects of disease modifying therapies Mario Habek, Cvetić Željko, Ana Savić Mlakar, Krešo Bendelja, Dunja Rogić, Ivan Adamec, et al. (+3)
124 [GO] 2022―Jan―25 Psychological impacts of COVID-19 pandemic on individuals living with multiple sclerosis: a rapid systematic review Amin Zarghami, Mohammad A. Hussain, Julie A. Campbell, Chigozie Ezegbe, Ingrid van der Mei, Bruce V. Taylor, Suzi B. Claflin
125 [GO] 2022―Jan―24 Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - a pilot study Moser Tobias, Otto Ferdinand, O′Sullivan Ciara, Hitzl Wolfgang, Pilz Georg, Harrer Andrea, et al. (+2)
126 [GO] 2022―Jan―24 Thermal dysregulation in patients with multiple sclerosis during SARS-CoV-2 infection. The potential therapeutic role of exercise Omid Razi, Bakhtyar Tartibian, Ana Maria Teixeira, Nastaran Zamani, Karuppasamy Govindasamy, Katsuhiko Suzuki, et al. (+2)
127 [GO] 2022―Jan―19 To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England Bastian Tugemann, Navid Manouchehri, Olaf Stuve
128 [GO] 2022―Jan―11 7Fingolimod impairs inactivated vaccine (CoronaVac)-induced antibody response to SARS-CoV-2 spike protein in persons with multiple sclerosis Recai Türkoğlu, Nesrin Baliç, Tuğçe Kızılay, Ruziye Erol, Ece Akbayır, Vuslat Yılmaz, Erdem Tüzün
129 [GO] 2022―Jan―10 Comparison of SARS-CoV-2 antibody response after two doses of mRNA and inactivated vaccines in multiple sclerosis patients treated with disease-modifying therapies Serkan Ozakbas, Cavid Baba, Yavuz Dogan, Sumeyye Cevik, Sinem Ozcelik, Ergi Kaya
130 [GO] 2022―Jan―08 Clinical Characteristics and Outcomes of Multiple Sclerosis Patients with COVID-19 in Toronto, Canada Jacqueline M. Solomon, Ashley Jones, Marika Hohol, Kristen M. Krysko, Alexandra Muccilli, Alexandra Roll, et al. (+6)
131 [GO] 2022―Jan―04 Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic Elle Levit, Inessa Cohen, Megan Dahl, Keith Edwards, Bianca Weinstock-Guttman, Toshinari Ishikawa, et al. (+11)
132 [GO] 2022―Jan―04 Surviving a global pandemic: The experience of depression, anxiety, and loneliness among individuals with multiple sclerosis L. Strober, E. Weber, A. Lequerica, N. Chiaravalloti
133 [GO] 2021―Dec―20 Pandemic-associated mental health changes in youth with neuroinflammatory disorders Lindsey M Logan, Samantha Stephens, Beyza Ciftci-Kavaklioglu, Tara Berenbaum, Mina Ly, Giulia Longoni, E Ann Yeh
134 [GO] 2021―Dec―18 Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects Giorgia Teresa Maniscalco, Valentino Manzo, Anne Lise Ferrara, Alessandro Perrella, Mariaelena Di Battista, Simona Salvatore, et al. (+15)
135 [GO] 2021―Dec―05 COVID-19 Vaccine Intent in Appalachian Patients with Multiple Sclerosis Hongyan Wu, Melanie Ward, Ashlyn Brown, Erica Blackwell, Amna Umer
136 [GO] 2021―Dec―05 Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in England Afagh Garjani, Sameer Patel, Dhiren Bharkhada, Waqar Rashid, Alasdair Coles, Graham R Law, Nikos Evangelou
137 [GO] 2021―Dec―04 CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis David Baker, Amy MacDougall, Angray S. Kang, Klaus Schmierer, Gavin Giovannoni, Ruth Dobson
138 [GO] 2021―Dec―02 Vaccination Against SARS-CoV-2 in Neuroinflammatory Disease: Early Safety/Tolerability Data Samantha Epstein, Zongqi Xia, Annie Lee, Megan Dahl, Keith Edwards, Elle Levit, et al. (+10)
139 [GO] 2021―Nov―30 Characteristics of COVID-19 in patients with multiple sclerosis Fereshteh Ghadiri, Mohammad Ali Sahraian, Vahid Shayegannejad, Fereshteh Ashtari, Hamidreza Ghalyanchi, Seyed Mohammad Baghbanian, et al. (+10)
140 [GO] 2021―Nov―30 Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod Magdalena Krbot Skorić, Dunja Rogić, Ivana Lapić, Dragana Šegulja, Mario Habek
141 [GO] 2021―Nov―23 Longitudinal humoral response after SARS-CoV-2 vaccination in ocrelizumab treated MS patients: to wait and repopulate? Z.L.E. van Kempen, L. Wieske, E.W. Stalman, L.Y.L Kummer, P.J. van Dam, A.G. Volkers, et al. (+15)
142 [GO] 2021―Nov―22 Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD Alessandro Dinoto, Elia Sechi, Sergio Ferrari, Alberto Gajofatto, Riccardo Orlandi, Paolo Solla, et al. (+9)
143 [GO] 2021―Nov―22 SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: same story, different vaccine Masoud Etemadifar, Nahad Sedaghat, Hosein Nouri, Noushin Lotfi, Ahmad Chitsaz, Reza Khorvash, et al. (+4)
144 [GO] 2021―Nov―19 The Turkish experience of Covid-19 Infection in people with NMOSD and MOGAD: a milder course? Sedat Sen, Asli Tuncer, Serkan Ozakbas, Cihat Uzunkopru, Cavid Baba, Serkan Demir, et al. (+31)
145 [GO] 2021―Nov―18 B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: a case-control study William L. Conte
146 [GO] 2021―Nov―10 A year with the fear of COVID-19 in Multiple Sclerosis Patients: Examination of depression, sleep quality and quality of life before and after the pandemic Kubra Yeni, Zeliha Tulek, Murat Terzi
147 [GO] 2021―Nov―10 COVID-19 outcomes in Persons with Multiple Sclerosis treated with Rituximab Rajesh B Iyer, Raghavendra S, Javeria Nooraine M, Jaychandran R
148 [GO] 2021―Nov―09 Humoral and T-Cell Responses to SARS-CoV-2 Vaccination in Multiple Sclerosis Patients Treated with Ocrelizumab J.D. Katz, A.J. Bouley, R.M. Jungquist, E.A. Douglas, I.L. O'Shea, E.S. Lathi
149 [GO] 2021―Nov―03 ¿Can COVID-19 exacerbate Multiple Sclerosis symptoms? A case series analysis. Gloria Michelena, Magdalena Casas, María Bárbara Eizaguirre, María Cecilia Pita, Leila Cohen, Ricardo Alonso, et al. (+2)
150 [GO] 2021―Nov―01 The study of COVID-19 infection following vaccination in patients with multiple sclerosis Fereshteh Ghadiri, Mohammad Ali Sahraian, Amirreza Azimi, Abdorreza Naser Moghadasi
151 [GO] 2021―Nov―01 COVID-19 Susceptibility and Outcomes among Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD): A Systematic Review and Meta-Analysis Mahdi Barzegar, Omid Mirmosayyeb, Narges Ebrahimi, Sara Bagherieh, Alireza Afshari-Safavi, Ali Mahdi Hosseinabadi, et al. (+2)
152 [GO] 2021―Oct―25 Effect of cladribine on COVID-19 serology responses following two doses of the BNT162b2 mRNA vaccine in patients with multiple sclerosis Livnat Brill, Ariel Rechtman, Omri Zveik, Nitzan Haham, Netta Levin, Alla Shifrin, et al. (+2)
153 [GO] 2021―Oct―25 Safety of Natalizumab reinfusion in Multiple Sclerosis patients during active Sars-Cov2 infection D. Landi, G. Cola, V. Mantero, R. Balgera, L. Moiola, A. Nozzolillo, et al. (+8)
154 [GO] 2021―Oct―22 COVID-19 and vaccination against SARS-CoV-2 in patients with neuromyelitis optica spectrum disorders Vanja Jovicevic, Jovana Ivanovic, Marko Andabaka, Olivera Tamas, Nikola Veselinovic, Nikola Momcilovic, et al. (+3)
155 [GO] 2021―Oct―19 COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: what we know by May 2021 Saba Naghavi, Aryan Kavosh, Iman Adib, Vahid Shaygannejad, Sina Arabi, Maryam Rahimi, et al. (+2)
156 [GO] 2021―Oct―19 Relationships between changes in daily occupations and health-related quality of life in persons with multiple sclerosis during the COVID-19 pandemic Yael Goverover, Michelle H. Chen, Amanda Botticello, Gerald T. Voelbel, Grace Kim, John DeLuca, Helen M. Genova
157 [GO] 2021―Oct―14 New relapse of multiple sclerosis and neuromyelitis optica as a potential adverse event of AstraZeneca AZD1222 vaccination for COVID-19 Yara D Fragoso, Sidney Gomes, Marcus Vinicius M Gonçalves, Euldes Mendes Junior, Bianca Etelvina S de Oliveira, Cristiane Franklin Rocha, et al. (+4)
158 [GO] 2021―Oct―12 Sociodemographic and clinical factors associated with depression, anxiety, and general mental health in people with multiple sclerosis during the COVID-19 pandemic Lauren Uhr, Dylan R. Rice, Farrah J. Mateen
159 [GO] 2021―Oct―09 COVID-19 in Multiple Sclerosis: Clinically reported outcomes from the UK Multiple Sclerosis Register Middleton RM, Craig EM, Rodgers WJ, Tuite-Dalton K, Garjani A, Evangelou N, et al. (+15)
160 [GO] 2021―Sep―28 Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis Mark S. Freedman, Dominic Jack, Zuzana Murgašová, Milorad Todorović, Andrea Seitzinger
161 [GO] 2021―Sep―28 Impact of COVID-19 Public Health Measures on Myelin Oligodendrocyte Glycoprotein IgG-Associated Disorders in Children Matsanga Leyila Kaseka, Mina Ly, Carmen Yea, Giulia Longoni, E. Ann Yeh
162 [GO] 2021―Sep―27 Current international trends in the treatment of multiple sclerosis in children -impact of the COVID-19 pandemic Fredrik Sandesjö, Evangeline Wassmer, Kumaran Deiva, Maria Pia Amato, Tanuja Chitnis, Cheryl Hemingway, et al. (+6)
163 [GO] 2021―Sep―27 Clinical impact of Ocrelizumab extended interval dosing during the COVID-19 pandemic and associations with CD19+ B-cell repopulation Nitin Kumar Sahi, Syed Muhammad Ali Abidi, Omar Salim, Roby Abraham, Seema Kalra, Adnan Al-Araji
164 [GO] 2021―Sep―17 Long COVID or post COVID-19 syndrome J. Lechner-Scott, M. Levy, C. Hawkes, A. Yeh, G. Giovannoni
165 [GO] 2021―Sep―13 Importance of T-cell response to COVID-19 vaccination in patients with multiple sclerosis treated by anti-CD20 therapies: New vaccines are required to be developed Abdorreza Naser Moghadasi
166 [GO] 2021―Sep―09 Humoral immune response following SARS-CoV-2 mRNA vaccination concomitant to anti-CD20 therapy in multiple sclerosis Frederik Novak, Anna Christine Nilsson, Christian Nielsen, Dorte K. Holm, Kamilla Østergaard, Anna Bystrup, et al. (+13)
167 [GO] 2021―Aug―25 MENACTRIMS Practice Guideline for COVID-19 Vaccination in Patients with Multiple Sclerosis Bassem I Yamout, Magd Zakaria, Jihad Inshasi, Mohammad Al-Jumah, Maya Zeineddine, Maurice Dahdaleh, et al. (+3)
168 [GO] 2021―Aug―16 COVID-19 severity and outcome in multiple sclerosis: results of a national, registry-based, matched cohort study Carlos A. Pérez, Guo-Qiang Zhang, Xiaojing Li, Yan Huang, John A. Lincoln, Rohini D. Samudralwar, et al. (+2)
169 [GO] 2021―Aug―08 Understanding the impacts of COVID-19 pandemic in people with multiple sclerosis treated with ocrelizumab Rosetta Pedotti, Erwan Muros-Le Rouzic, Catarina Raposo, Sven Schippling, Nikki Jessop
170 [GO] 2021―Aug―02 Patient-reported safety and tolerability of the COVID-19 vaccines in persons with rare neuroimmunological diseases Itay Lotan, Gabriela Romanow, Michael Levy
171 [GO] 2021―Jul―31 The comparison of fatigue, sleep quality, physical activity, quality of life, and psychological status in multiple sclerosis patients with or without COVID-19 Mehmet Özkeskin, Fatih Özden, Bedriye Karaman, Özgül Ekmekçi, Nur Yüceyar
172 [GO] 2021―Jul―27 Willingness to receive a COVID-19 vaccine in people with multiple sclerosis - UK MS Register Survey Yun Huang, William J Rodgers, Rodden M Middleton, Aravindhan Baheerathan, Katherine A Tuite-Dalton, David V Ford, et al. (+2)
173 [GO] 2021―Jul―25 Coronavirus disease 2019 in Latin American patients with multiple sclerosis Yara D. Fragoso, Irene Schiavetti, Luca Carmisciano, Marta Ponzano, Judith Steinberg, Irene Treviño-Frenk, et al. (+10)
174 [GO] 2021―Jul―24 Cerebrospinal Fluid Cytokine, Chemokine, and SARS-CoV-2 antibody profiles in children with neuropsychiatric symptoms associated with COVID-19 Binh Ngo, Stacey A. Lapp, Benjamin Siegel, Vikash Patel, Laila Hussaini, Sonali Bora, et al. (+6)
175 [GO] 2021―Jul―22 COVID-19 vaccine hesitancy in adults with multiple sclerosis in the United States: A follow up survey during the initial vaccine rollout in 2021 Dawn M. Ehde, Michelle K. Roberts, Andrew T. Humbert, Tracy E. Herring, Kevin N. Alschuler
176 [GO] 2021―Jul―21 T-cell responses to SARS-CoV-2 in Multiple Sclerosis patients treated with ocrelizumab healed from COVID-19 with absent or low anti-Spike antibody titers Marco Iannetta, Doriana Landi, Gaia Cola, Vincenzo Malagnino, Elisabetta Teti, Daniela Fraboni, et al. (+7)
177 [GO] 2021―Jul―19 Outcomes of COVID-19 Infection in Multiple Sclerosis and Related Conditions: One-Year Pandemic Experience of the Multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC) Sylvia Klineova, Asaff Harel, Rebecca Straus Farber, Tracy DeAngelis, Yinan Zhang, Roland Hentz, et al. (+5)
178 [GO] 2021―Jul―18 COVID-19 vaccines and multiple sclerosis disease-modifying therapies Gavin Giovannoni, Christopher H. Hawkes, Jeannette Lechner-Scott, Michael Levy, E. Ann Yeh, David Baker
179 [GO] 2021―Jul―16 Key points to keep in mind related to COVID-19 vaccines in people with multiple sclerosis Lorna Galleguillos, Ricardo Alonso
180 [GO] 2021―Jul―15 HUMORAL RESPONSE TO SARS-CoV-2 AND COVID-19 VACCINES IN PATIENTS WITH MULTIPLE SCLEROSIS TREATED WITH IMMUNE RECONSTITUTION THERAPIES Jelena Drulovic, Jovana Ivanovic, Vanja Martinovic, Olivera Tamas, Nikola Veselinovic, Danica Cujic, et al. (+3)
181 [GO] 2021―Jul―13 Oral administration of methylprednisolone powder for intravenous injection dissolved in water to treat MS and NMOSD relapses during COVID-19 pandemic in a real-world setting Geraldine G. Luetic, María Laura Menichini, Óscar Fernández
182 [GO] 2021―Jul―02 Outcomes of COVID-19 in people with multiple sclerosis treated with cladribine tablets: an update Dominic Jack, Doris Damian, Axel Nolting, Andrew Galazka
183 [GO] 2021―Jul―02 Risk factors for COVID-19 infection in patients with multiple sclerosis: a nested case-control study Lauren Uhr, Hollie Schmidt, Farrah J. Mateen
184 [GO] 2021―Jul―02 Is natalizumab a safe treatment for patients with multiple sclerosis in the COVID-19 pandemic? Data from the first year of the pandemic Judit Díaz-Díaz, Clara Isabel Ramirez, Marta Ortiz-Pica, Elena García-Yusta, Irene Gómez-Estevez, Celia Oreja-Guevara
185 [GO] 2021―Jun―30 Changes on the Health Care of People with Multiple Sclerosis from Latin America during the COVID-19 Pandemic Anibal Chertcoff, Johana Bauer, Berenice Anabel Silva, Mayra Aldecoa, María Bárbara Eizaguirre, Roberto Rodriguez, et al. (+23)
186 [GO] 2021―Jun―26 Opinions, beliefs and knowledge of people with multiple sclerosis on COVID-19 pandemic and vaccine Joana Moniz Dionísio, Mariana Santos, Ana Martins Rodrigues, André Rêgo, Joana Vítor, Sofia Delgado, et al. (+7)
187 [GO] 2021―Jun―24 Frequency and characteristics of falls in people living with and without multiple sclerosis during the COVID-19 pandemic: a cross-sectional online survey Tobia Zanotto, Mikaela L Frechette, Stephen R Koziel, Katherine L Hsieh, Jacob J Sosnoff
188 [GO] 2021―Jun―24 Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in the Czech Republic Dominika Stastna, Ingrid Menkyova, Jiri Drahota, Aneta Mazouchova, Jana Adamkova, Radek Ampapa, et al. (+10)
189 [GO] 2021―Jun―02 Fear of COVID-19, problems accessing medical appointments, and subjective experience of disease progression, predict anxiety and depression reactions in patients with Multiple Sclerosis Broche-Pérez Yunier, Rodneys M. Jiménez-Morales, Laura Ortiz Monasterio-Ramos, Lázaro A. Vázquez-Gómez, Zoylen Fernández-Fleites
190 [GO] 2021―May―30 COVID-19 in Argentine teriflunomide-treated multiple sclerosis patients: first national case series. Geraldine Luetic, María L. Menichini, Marcos Burgos, Ricardo Alonso, Edgar Carnero Contentti, Adriana Carrá, et al. (+3)
191 [GO] 2021―May―30 A Commentary Letter on “Can Coronavirus Disease 2019 (COVID-19) Trigger Exacerbation of Multiple Sclerosis? A Retrospective Study” Nahad Sedaghat
192 [GO] 2021―May―27 The impact of COVID-19 home confinement on neuromuscular performance, functional capacity, and psychological state in Spanish people with Multiple Sclerosis Luis Andreu-Caravaca, Domingo J. Ramos-Campo, Linda H. Chung, Pedro Manonelles, Oriol Abellán-Aynés, Jacobo Á. Rubio-Arias
193 [GO] 2021―May―25 The effect of the Australian bushfires and the COVID-19 pandemic on health behaviours in people with multiple sclerosis CH Marck, A Hunter, B Heritage, L Gibbs, AG Kermode, DI Walker, YC Learmonth
194 [GO] 2021―May―24 Coping with stress during the first wave of the COVID-19 pandemic by Turkish people with Multiple Sclerosis: the relationship between perceived stress and quality of life Bengu Altunan, Aysun Unal, Ayhan Bingöl, Filiz Dilek, Derya Girgin
195 [GO] 2021―May―18 Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis K. Allen-Philbey, A. Stennett, T. Begum, AC. Johnson, R. Dobson, G. Giovannoni, et al. (+7)
196 [GO] 2021―May―07 Attenuation of antibody response to SARS-CoV-2 infection in patients with multiple sclerosis on ocrelizumab: a case-control study William L. Conte
197 [GO] 2021―May―07 Registry of patients with multiple sclerosis and COVID-19 infection in Saudi Arabia Foziah Alshamrani, Hind Alnajashi, Mohammed Aljumah, Mohammad Almuaigel, Yaser Almalik, Seraj Makkawi, et al. (+9)
198 [GO] 2021―May―05 COVID-19 is associated with new symptoms of multiple sclerosis that are prevented by disease modifying therapies Afagh Garjani, Rodden M Middleton, Rachael Hunter, Katherine A Tuite-Dalton, Alasdair Coles, Ruth Dobson, et al. (+8)
199 [GO] 2021―May―04 COVID-19 vaccines in multiple sclerosis treated with cladribine or ocrelizumab Fabio Buttari, Antonio Bruno, Ettore Dolcetti, Federica Azzolini, Paolo Bellantonio, Diego Centonze, Roberta Fantozzi
200 [GO] 2021―Apr―28 The course of COVID-19 infection in patients with multiple sclerosis - the experience of one center based on the population of Upper Silesia Maria Nowak-Kiczmer, Katarzyna Kubicka-Bączyk, Natalia Niedziela, Bożena Adamczyk, Krzysztof Wierzbicki, Wojciech Bartman, Monika Adamczyk-Sowa
201 [GO] 2021―Apr―14 Can Coronavirus Disease 2019 (COVID-19) Trigger Exacerbation of Multiple Sclerosis? A Retrospective Study Mahdi Barzegar, Saeed Vaheb, Omid Mirmosayyeb, Alireze Afshari-Safavi, Nasim Nehzat, Vahid Shaygannejad
202 [GO] 2021―Mar―27 COVID-19 in patients with multiple sclerosis treated with cladribine tablets: An update Dominic Jack, Doris Damian, Axel Nolting, Andrew Galazka
203 [GO] 2021―Mar―25 Reactivation of SARS-CoV-2 after Rituximab in a Patient with Multiple Sclerosis Gauruv Bose, Kristin Galetta
204 [GO] 2021―Mar―21 COVID-19 and the Risk of Relapse in Multiple Sclerosis Patients: A Fight with No Bystander Effect? Masoud Etemadifar, Nahad Sedaghat, Ali Aghababaee, Parisa K Kargaran, Mohammad Reza Maracy, Mazdak Ganjalikhani-Hakemi, et al. (+5)
205 [GO] 2021―Mar―21 COVID-19 and emerging spinal cord complications: A systematic review Ritwick Mondal, Shramana Deb, Gourav Shome, Upasana Ganguly, Durjoy Lahiri, Julián Benito-Leon
206 [GO] 2021―Mar―14 Sars-Cov-2 infection related inflammatory and demyelinating disease; a brief case series Nurhan Kaya Tutar, Sami Omerhoca, Eda Coban, Nilufer Kale
207 [GO] 2021―Mar―09 B cell therapy and the use of RNA-based COVID-19 vaccines Anastasia Vishnevetsky, Chris Hawkes, Jeannette Lechner-Scott, Gavin Giovannoni, Michael Levy
208 [GO] 2021―Mar―07 COVID-19 in multiple sclerosis and neuromyelitis optica spectrum disorder patients in Latin America Ricardo Alonso, Berenice Silva, Orlando Garcea, Patricio E. Correa Diaz, Giordani Rodrigues dos Passos, Deyanira A. Ramirez Navarro, et al. (+48)
209 [GO] 2021―Mar―07 Willingness to be vaccinated against COVID-19: an exploratory online survey in a Portuguese cohort of multiple sclerosis patients Filipa Serrazina, André Sobral Pinho, Gonçalo Cabral, Manuel Salavisa, Ana Sofia Correia
210 [GO] 2021―Feb―24 COVID-19 in a temporal relation to the onset of multiple sclerosis Yara D. Fragoso, Filippe A.S. Pacheco, Guilherme L. Silveira, Rodrigo A. Oliveira, Vitor M. Carvalho, Ana Luiza C. Martimbianco
211 [GO] 2021―Feb―23 Perceptions of risk and adherence to care in MS patients during the COVID-19 pandemic: a cross-sectional study Yinan Zhang, Erin Staker, Gary Cutter, Stephen Krieger, Aaron E Miller
212 [GO] 2021―Feb―23 MOG-associated encephalitis following SARS-COV-2 Infection John Peters, Saleh Alhasan, Chantal B.F. Vogels, Nathan D. Grubaugh, Shelli Farhadian, Erin E. Longbrake
213 [GO] 2021―Feb―23 Immunotherapy Responsive SARS-CoV-2 Infection Exacerbating Opsoclonus Myoclonus Syndrome Sarah E. Wiegand, Wendy G. Mitchell, Jonathan D. Santoro
214 [GO] 2021―Jan―29 COVID-19 and Disease-Modifying Therapies in Patients with Demyelinating Diseases of the Central Nervous System: A Systematic Review Maryam Sharifian-Dorche, Mohammad Ali Sahraian, Giulia Fadda, Michael Osherov, Amirhossein Sharifian-Dorche, Maryam Karaminia, et al. (+4)
215 [GO] 2021―Jan―29 Fear and anxiety in patients with multiple sclerosis during COVID-19 pandemic; report of an Iranian population Neda Ramezani, Fereshteh Ashtari, Elahe Abdi Bastami, Kimia Ghaderi, Sayed Mohsen Hosseini, Maryam Kazemi Naeini, et al. (+2)
216 [GO] 2021―Jan―22 Willingness to obtain COVID-19 vaccination in adults with multiple sclerosis in the United States Dawn M. Ehde, Michelle K. Roberts, Tracy E. Herring, Kevin N. Alschuler
217 [GO] 2021―Jan―21 Para-infectious anti-GD2/GD3 IgM myelitis during the Covid-19 pandemic: case report and literature review. Rodríguez de Antonio(Luis Alberto), González Suárez(Inés), Fernández Barriuso(Inés), Rabasa Pérez(María)
218 [GO] 2021―Jan―19 COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: implication for vaccination program? Stefano Gelibter, Mario Orrico, Massimo Filippi, Lucia Moiola
219 [GO] 2021―Jan―19 Development of SARS-CoV-2 IgM and IgG antibodies in a Relapsing Multiple Sclerosis patient on Ofatumumab Ramon E Flores-Gonzalez, Jeffrey Hernandez, Leticia Tornes, Kottil Rammohan, Silvia Delgado
220 [GO] 2021―Jan―14 Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients Giulia Mallucci, Antonio Zito, Fausto Baldanti, Matteo Gastaldi, Beatrice Dal Fabbro, Diego Franciotta, Roberto Bergamaschi
221 [GO] 2021―Jan―02 COVID-19 in teriflunomide-treated patients with multiple sclerosis: a case report and literature review. Fioravante Capone, Francesco Motolese, Tiziano Luce, Mariagrazia Rossi, Alessandro Magliozzi, Vincenzo Di Lazzaro
222 [GO] 2020―Dec―30 COVID-19 in ocrelizumab-treated people with multiple sclerosis Richard Hughes, Louise Whitley, Kocho Fitovski, Hans-Martin Schneble, Erwan Muros, Annette Sauter, et al. (+6)
223 [GO] 2020―Dec―25 Longitudinally extensive transverse myelitis following acute COVID-19 infection Thibault Fumery, Coline Baudar, Michel Ossemann, Frédéric London
224 [GO] 2020―Dec―24 Pandemic Forward: Lessons learned and expert perspectives on multiple sclerosis care in the COVID-19 era Jacqueline A. Nicholas, Robert K Shin, Enrique Alvarez, Barry Hendin, Kavita V. Nair, Fred D. Lublin
225 [GO] 2020―Dec―21 Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness Barbara Barun, Tereza Gabelić, Ivan Adamec, Antonija Babić, Hrvoje Lalić, Drago Batinić, et al. (+2)
226 [GO] 2020―Dec―19 Experience of South American MS and/or NMOSD experts in practice during the COVID-19 pandemic: focus on Telemedicine Ricardo Alonso, René Carvajal, Mateus Boaventura, Lorna Galleguillos
227 [GO] 2020―Dec―01 Fast and safe: Optimising multiple sclerosis infusions during COVID-19 pandemic Louise Rath, Minh Viet Bui, Julian Ellis, John Carey, Josephine Baker, Lisa Taylor, et al. (+12)
228 [GO] 2020―Nov―05 Distress and risk perception in people living with multiple sclerosis during the early phase of the COVID-19 pandemic Kevin N. Alschuler, Michelle K. Roberts, Tracy E. Herring, Dawn M. Ehde
229 [GO] 2020―Oct―27 Physical activity behavior in people with multiple sclerosis during the COVID-19 pandemic in Israel: Results of an online survey Alon Kalron, Mark Dolev, Michal Greenberg-Abrahami, Shay Menascu, Lior Frid, Sharon Avrech-Shezifi, et al. (+3)
230 [GO] 2020―Oct―27 Can dexamethasone prevent the seizures induced by SARS-CoV-2 infection? Adriana Fernanda K. Vizuete, Carlos-Alberto Gonçalves
231 [GO] 2020―Oct―26 THE IMPACT OF SARS-COV 2 ON THE ANXIETY LEVELS OF SUBJECTS AND ON THE ANXIETY AND DEPRESSION LEVELS OF THEIR PARENTS Tugce Damla Dilek, Zehra Boybay, Nursena Kologlu, Oguzhan Tin, Serhat Güler, Sema Saltık
232 [GO] 2020―Oct―23 Rapid transfer of knowledge for multiple sclerosis clinical care during COVID-19: ECHO MS Kevin N. Alschuler, Gloria von Geldern, Darren Ball, Kathleen Costello, Mark Skeen, Salim Chahin, Annette Wundes
233 [GO] 2020―Oct―21 Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment Fabio Giuseppe Masuccio, Marianna Lo Re, Antonio Bertolotto, Marco Capobianco, Claudio Solaro
234 [GO] 2020―Oct―13 Are multiple sclerosis patients and their caregivers more anxious and more committed to following the basic preventive measures during the COVID-19 pandemic? Farouk Talaat, Ismail Ramadan, Salma Aly, Eman Hamdy
235 [GO] 2020―Oct―03 Mental health status of Relapsing-Remitting Multiple Sclerosis Italian patients returning to work soon after the easing of lockdown during COVID-19 pandemic: a monocentric experience Aurora Zanghì, Emanuele D'Amico, Maria Luca, Marco Ciaorella, Lucia Basile, Francesco Patti
236 [GO] 2020―Sep―29 Could Sars-Cov2 affect MS progression? Arianna Di Stadio, Luigina Romani, Evanthia Bernitsas
237 [GO] 2020―Sep―28 How does the COVID-19 cause seizure and epilepsy in patients? The potential mechanisms Farnaz Nikbakht, Ali Mohammadkhanizadeh, Ekram Mohammadi
238 [GO] 2020―Sep―19 Impact of the COVID-19 Pandemic on the Health Care of >1,000 People Living with Multiple Sclerosis: A cross-sectional study Andre C. Vogel, Hollie Schmidt, Sara Loud, Robert McBurney, Farrah J. Mateen
239 [GO] 2020―Sep―16 Evaluating the perspective of patients with MS and related conditions on their DMT in relation to the COVID-19 pandemic in one MS centre in Australia Nabil Seery, Vivien Li, Ai-Lan Nguyen, Izanne Roos, Katherine A Buzzard, Roberts Atvars, et al. (+10)
240 [GO] 2020―Sep―03 Beyond COVID-19: do MS/NMO-SD patients treated with anti-CD20 therapies develop SARS-CoV2 antibodies ? Elisabeth Maillart, Caroline Papeix, Catherine Lubetzki, Thomas Roux, Valérie Pourcher, Céline Louapre
241 [GO] 2020―Sep―01 Neuromyelitis optica spectrum disorder after presumed coronavirus (COVID-19) infection: A case report Naomi S. de Ruijter, Gerrit Kramer, Rob A.R. Gons, Gerald J.D. Hengstman
242 [GO] 2020―Aug―30 Normal antibody response after COVID-19 during treatment with cladribine Elisabeth G. Celius
243 [GO] 2020―Aug―29 Evaluation of the rate of COVID-19 infection, hospitalization and death among Iranian patients with multiple sclerosis Mohammad Ali Sahraian, Amirreza Azimi, Samira Navardi, Sara Ala, Abdorreza Naser Moghadasi
244 [GO] 2020―Aug―27 Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets Dominic Jack, Axel Nolting, Andrew Galazka
245 [GO] 2020―Aug―20 Would it be recommended treating multiple sclerosis relapses with high dose oral instead intravenous steroids during the COVID-19 pandemic? Yes. Constanza Segamarchi, Berenice Silva, Patricia Saidon, Orlando Garcea, Ricardo Alonso
246 [GO] 2020―Aug―19 Assessing the susceptibility to acute respiratory illness COVID-19-related in a cohort of multiple sclerosis patients Vittorio Mantero, Lucia Abate, Roberto Balgera, Paola Basilico, Andrea Salmaggi, Christian Cordano
247 [GO] 2020―Aug―16 Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice Marcello De Angelis, Maria Petracca, Roberta Lanzillo, Vincenzo Brescia Morra, Marcello Moccia
248 [GO] 2020―Aug―10 COVID-19 in a multiple sclerosis (MS) patient treated with alemtuzumab: insight to the immune response after COVID Celsi Fiorella, Galleguillos Lorna
249 [GO] 2020―Aug―04 Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab Marco Iannetta, Novella Cesta, Christof Stingone, Vincenzo Malagnino, Elisabetta Teti, Pietro Vitale, et al. (+11)
250 [GO] 2020―Jul―31 The multiple sclerosis (MS) drugs as a potential treatment of ARDS in COVID-19 patients Malgorzata Kloc, Rafik M. Ghobrial
251 [GO] 2020―Jul―19 Asymptomatic SARS-CoV-2 infection in two patients with multiple sclerosis treated with fingolimod Giulia Mallucci, Antonio Zito, Beatrice Dal Fabbro, Roberto Bergamaschi
252 [GO] 2020―Jul―17 COVID-19 and multiple sclerosis: A description of two cases on alemtuzumab Eva Fernández-Díaz, Julia Gracia-Gil, Jose Gregorio García-García, María Palao, Carlos M Romero-Sánchez, Tomás Segura
253 [GO] 2020―Jul―16 Psychological status of patients with relapsing-remitting multiple sclerosis during coronavirus disease-2019 outbreak Aleksandar Stojanov, Marina Malobabic, Vuk Milosevic, Jelena Stojanov, Slobodan Vojinovic, Goran Stanojevic, Milos Stevic
254 [GO] 2020―Jul―12 COVID-19 in MS and NMOSD: A multicentric online national survey in Chile Ethel Ciampi, Reinaldo Uribe-San-Martín, Bernardita Soler, Ramiro Fernández, Pía García, Claudio Navarrete-Asenjo, et al. (+6)
255 [GO] 2020―Jul―07 Multiple Sclerosis following SARS-CoV-2 infection M. Palao, E. Fernández-Díaz, J. Gracia-Gil, C.M. Romero-Sánchez, I. Díaz-Maroto, T. Segura
256 [GO] 2020―Jul―06 Attitudes of patients with relapsing-remitting form of multiple sclerosis using disease-modifying drugs in Montenegro regarding COVID-19 pandemic Ljiljana Radulovic, Jevto Erakovic, Milovan Roganovic
257 [GO] 2020―Jul―04 Frequency and severity of COVID-19 in multiple sclerosis: A short single-site report from northern Italy Francesco Crescenzo, Damiano Marastoni, Chiara Bovo, Massimiliano Calabrese
258 [GO] 2020―Jul―03 Management of Idiopathic CNS inflammatory diseases during the COVID-19 pandemic: Perspectives and strategies for continuity of care from a South East Asian Center with limited resources. S. Viswanathan
259 [GO] 2020―Jul―03 Adherence to social distancing and use of personal protective equipment and the risk of Sars-COV-2 infection in a cohort of patients with Multiple Sclerosis Landi D, Ponzano M, Nicoletti CG, Cecchi G, Cola G, Mataluni G, et al. (+3)
260 [GO] 2020―Jun―30 The impact of COVID-19 on patients with Neuromyelitis Optica Spectrum Disorder; a pilot study Anna Tomczak, May H. Han
261 [GO] 2020―Jun―26 Negative SARS-CoV-2 Antibody Testing Following COVID-19 Infection in Two MS Patients Treated with Ocrelizumab Jeanine Rempe Thornton, Asaff Harel
262 [GO] 2020―Jun―24 A case of possible atypical demyelinating event of the central nervous system following COVID-19 Anahita Zoghi, Mahtab Ramezani, Mehrdad Roozbeh, Ilad Alavi Darzam, Mohammad Ali Sahraian
263 [GO] 2020―Jun―23 Is serological response to SARS-CoV-2 preserved in MS patients on ocrelizumab treatment? A case report Matteo Lucchini, Assunta Bianco, Paola Del Giacomo, Chiara De Fino, Viviana Nociti, Massimiliano Mirabella
264 [GO] 2020―Jun―21 Decision-making on management of ms and nmosd patients during the COVID-19 pandemic: A latin american survey Alonso Ricardo, Carnero Contentti Edgar, Silva Berenice Anabel, López Pablo Adrian, Garcea Orlando, Hamuy Fernando, et al. (+3)
265 [GO] 2020―Jun―20 Mild COVID-19 infection in a patient with multiple sclerosis and severe depletion of T-lymphocyte subsets due to alemtuzumab Carlos Guevara, Eduardo Villa, Marcela Cifuentes, Rodrigo Naves, José de Grazia
266 [GO] 2020―Jun―20 Attenuation of antibody response to SARS-CoV-2 in a patient on ocrelizumab with hypogammaglobulinemia. WL Conte
267 [GO] 2020―Jun―16 Estimating the risk of COVID-19 in multiple sclerosis patients in Buenos Aires, Argentina E Cristiano, L Patrucco, JI Rojas, S Nuñez
268 [GO] 2020―Jun―15 COVID-19 IN 7 MULTIPLE SCLEROSIS PATIENTS IN TREATMENT WITH ANTI-CD20 THERAPIES Dra. Virginia Meca-Lallana, Dra. Clara Aguirre, Dra. Laura Cardeñoso, Dra. Teresa Alarcon, Dr. José Vivancos
269 [GO] 2020―Jun―11 Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab Jorge Matías-Guiu, Paloma Montero-Escribano, Vanesa Pytel, Jesús Porta-Etessam, Jordi A. Matias-Guiu
270 [GO] 2020―Jun―10 COVID-19 prevention and multiple sclerosis management: the SAFE pathway for the post-peak Antonio Buonomo, Vincenzo Brescia Morra, Emanuela Zappulo, Roberta Lanzillo, Ivan Gentile, Emma Montella, et al. (+3)
271 [GO] 2020―Jun―08 Characteristics of COVID-19 disease in multiple sclerosis patients Mahdi Barzegar, Omid Mirmosayyeb, Mahsa Ghajarzadeh, Nasim Nehzat, Saeed Vaheb, Vahid Shaygannejad, Reza Vosoughi
272 [GO] 2020―Jun―03 Covid-19 in a Patient With Multiple Sclerosis Treated With Natalizumab: May the Blockade of Integrins Have a Protective Role? Clara Aguirre, Virginia Meca-Lallana, Ana Barrios-Blandino, Beatriz del Río, Jose Vivancos
273 [GO] 2020―Jun―03 Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis Sara Salama, Gavin Giovannoni, Christopher H. Hawkes, Jeannette Lechner-Scott, Emmanuelle Waubant, Michael Levy
274 [GO] 2020―Jun―02 Evaluation of COVID-19 Infection in Patients with Neuromyelitis optica spectrum disorder (NMOSD): A Report from Iran Mohammad Ali Sahraian, Amirreza Azimi, Samira Navardi, Nasim Rezaeimanesh, Abdorreza Naser Moghadasi
275 [GO] 2020―Jun―02 Current and Emerging Therapeutics for Neuromyelitis Optica Spectrum Disorder: Relevance to the COVID-19 Pandemic Hesham Abboud, Crystal Zheng, Indrani Kar, Claire Kaori Chen, Crystal Sau, Alessandro Serra
276 [GO] 2020―Jun―02 ESTABLISHMENT OF A SAFETY PROTOCOL FOR THE ADMINISTRATION OF TREATMENTS IN MULTIPLE SCLEROSIS DURING THE SARS-CoV-2 PANDEMIC Virginia Meca-Lallana, Clara Aguirre, Laura Cardeñoso, Teresa Alarcon, Angels Figuerola-Tejerina, Beatriz del Río, et al. (+2)
277 [GO] 2020―May―23 Favorable outcome after COVID-19 infection in a multiple sclerosis patient initiated on ocrelizumab during the pandemic Mahsa Ghajarzadeh, Omid Mirmosayyeb, Mahdi Barzegar, Nasim Nehzat, Saeed Vaheb, Vahid Shaygannejad, Amir-Hadi Maghzi
278 [GO] 2020―May―23 Treating patients with multiple sclerosis during the COVID-19 pandemic: Assessing the expert recommendations Carlos Guevara, Eduardo Villa, Carlos Silva Rosas, Violeta Diaz, Rodrigo Naves
279 [GO] 2020―May―19 Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis Optica spectrum disorder. Marina Creed, Enrique Ballesteros, L. John Greenfield Jr, Jaime Imitola
280 [GO] 2020―May―16 COVID-19 in persons with multiple sclerosis treated with ocrelizumab - a pharmacovigilance case series Richard Hughes, Rosetta Pedotti, Harold Koendgen
281 [GO] 2020―May―16 COVID-19 pandemic: the experience of a multiple sclerosis centre in Chile Ethel Ciampi, Reinaldo Uribe-San-Martin, Claudia Cárcamo
282 [GO] 2020―May―16 Are Type 1 Interferons treatment in Multiple Sclerosis as a potential therapy against COVID-19? Emin GEMCIOGLU, Mehmet DAVUTOGLU, Ese Ece OZDEMIR, Abdulsamet ERDEN
283 [GO] 2020―May―15 Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab Kulachanya Suwanwongse, Nehad Shabarek
284 [GO] 2020―May―14 Knowledge regarding COVID-19 pandemic in patients with Multiple sclerosis (MS): A report from Iran Mohammad Ali Sahraian, Mohammad Reza Gheini, Nasim Rezaeimanesh, Mahsa Ghajarzadeh, Abdorreza Naser Moghadasi
285 [GO] 2020―May―13 B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with Multiple Sclerosis during the early COVID-19 epidemic in Iran Farinaz Safavi, Bardia Nourbakhsh, Amir Reza Azimi
286 [GO] 2020―May―12 The underpinning biology relating to multiple sclerosis disease modifying treatments during the COVID-19 pandemic. David Baker, Sandra Amor, Angray S. Kang, Klaus Schmierer, Gavin Giovannoni
287 [GO] 2020―May―08 A fine balance: Immunosuppression and immunotherapy in a patient with multiple sclerosis and COVID-19 Cristina Valencia-Sanchez, Dean M. Wingerchuk
288 [GO] 2020―May―07 Anti-CD20 and COVID-19 in multiple sclerosis and related disorders: A case series of 60 patients from Madrid, Spain Paloma Montero-Escribano, Jorge Matías-Guiu, Patricia Gómez-Iglesias, Jesús Porta-Etessam, Vanesa Pytel, Jordi A. Matias-Guiu
289 [GO] 2020―May―06 Severe COVID-19 infection in a patient with multiple sclerosis treated with fingolimod Christian Foerch, Lucie Friedauer, Boris Bauer, Timo Wolf, Elisabeth H. Adam
290 [GO] 2020―Apr―30 Adamantanes might be protective from COVID-19 in patients with neurological diseases: multiple sclerosis, parkinsonism and cognitive impairment Konrad Rejdak, Paweł Grieb
291 [GO] 2020―Apr―30 COVID-19 occurring during Natalizumab treatment: a case report in a patient with extended interval dosing approach Giovanna Borriello, Antonio Ianniello
292 [GO] 2020―Apr―30 Neuropsychiatric and cognitive effects of the COVID-19 outbreak on multiple sclerosis patients Fahimeh Haji Akhoundi, Mohammad Ali Sahraian, Abdorreza Naser Moghadasi
293 [GO] 2020―Apr―22 Rethinking high-risk groups in COVID-19 Anastasia Vishnevetsky, Michael Levy
294 [GO] 2020―Apr―20 One Aspect of Coronavirus disease (COVID-19) Outbreak in Iran: High Anxiety among MS Patients Abdorreza Naser Moghadasi
295 [GO] 2020―Apr―18 Anti-CD20 immunosuppressive disease-modifying therapies and COVID-19 Gavin Giovannoni
296 [GO] 2020―Apr―18 The importance of being a Neurologist (during a dramatic pandemic) Stefano Gelibter
297 [GO] 2020―Apr―15 COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Giovanni Novi, Malgorzata Mikulska, Federica Briano, Federica Toscanini, Francesco Tazza, Antonio Uccelli, Matilde Inglese
298 [GO] 2020―Apr―05 Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge Edgar Carnero Contentti, Jorge Correa
299 [GO] 2020―Mar―28 The COVID-19 pandemic and the use of MS disease-modifying therapies Gavin Giovannoni, Chris Hawkes, Jeannette Lechner-Scott, Michael Levy, Emmanuelle Waubant, Julian Gold
 [1] 

299 Results       Page 1


[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.021 sec